Compounds > 4-[4-(4-methylphenyl)sulfonyl-1-piperazinyl]-2-thiophen-2-ylquinazoline
Page last updated: 2024-11-13

4-[4-(4-methylphenyl)sulfonyl-1-piperazinyl]-2-thiophen-2-ylquinazoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID26450846
CHEMBL ID1357878
CHEBI ID93300

Synonyms (13)

Synonym
NCGC00182291-01
NCGC00182291-02
NCGC00182291-03
smr001600484
2-(thiophen-2-yl)-4-(4-(p-tolylsulfonyl)piperazin-1-yl)quinazoline
MLS002728991
CHEMBL1357878
Z31097345
CHEBI:93300
Q27165012
4-[4-(4-methylphenyl)sulfonyl-1-piperazinyl]-2-thiophen-2-ylquinazoline
AKOS034151566
4-[4-(4-methylphenyl)sulfonylpiperazin-1-yl]-2-thiophen-2-ylquinazoline
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency10.69570.000811.382244.6684AID686978; AID686979
glucocerebrosidaseHomo sapiens (human)Potency2.27770.01268.156944.6684AID2588; AID2590; AID2595
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID577521Binding affinity to recombinant Gcase assessed as change in melting temperature at 50 uM by fluorescence thermal shift technique2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID577524Binding affinity to recombinant Gcase assessed as change in melting temperature at 1 uM by fluorescence thermal shift technique2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID577525Binding affinity to recombinant Gcase assessed as change in melting temperature at 0.1 uM by fluorescence thermal shift technique2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID577523Binding affinity to recombinant Gcase assessed as change in melting temperature at 10 uM by fluorescence thermal shift technique2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID577520Binding affinity to recombinant Gcase assessed as change in melting temperature at 100 uM by fluorescence thermal shift technique2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID577330Activity at recombinant Gcase N370S mutant in human spleen homogenates assessed as half maximal activity concentration of hydrolysis of 4-MU-beta-D-glucose2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID577522Binding affinity to recombinant Gcase assessed as change in melting temperature at 25 uM by fluorescence thermal shift technique2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID577514Inhibition of alpha-galactosidase2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID577519Binding affinity to recombinant Gcase assessed as change in melting temperature at 200 uM by fluorescence thermal shift technique2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID577513Inhibition of alpha-glucosidase2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
AID577333Binding affinity to recombinant Gcase assessed as change in melting temperature by fluorescence thermal shift technique2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-deoxynojirimycin
1-deoxy-nojirimycin: structure in first source. duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.		2.06102-(hydroxymethyl)piperidine-3,4,5-triol;
piperidine alkaloid		anti-HIV agent;
anti-obesity agent;
bacterial metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
hypoglycemic agent;
plant metabolite
isofagomine
[no description available]		2.0610piperidines
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Acid beta-Glucosidase Deficiency
[description not available]		02.0610
Gaucher Disease
An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (GLUCOSYLCERAMIDASE) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the MONONUCLEAR PHAGOCYTE SYSTEM. The characteristic Gaucher cells, glycosphingolipid-filled HISTIOCYTES, displace normal cells in BONE MARROW and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement.		02.0610